ITI Pharma and Healthcare Fund
Fund managers: Animesh Singh; Nilay Dalal
Benchmark: Nifty Healthcare Total Return Index · Riskometer: Very High · SEBI category, as filed: Sectoral/Thematic Funds · Allotted 8 Nov 2021
Source: AMFI scheme summary document
The scheme's yearly running cost as a % of its assets, taken out of the NAV a little each day. A regular plan costs more: it pays a distributor's commission.
Category median: direct 1.23 %, regular 2.40 % (174 schemes) · Regular costs ₹1,710 more a year per ₹1 lakh
Of this, the base expense ratio, the part SEBI caps: direct 0.58 %, regular 2.10 %. The rest is brokerage, transaction costs and statutory levies such as GST and STT, as AMFI's file lists them.
A year, as of 21 Nov 2026. Source: AMFI · Glossary: TER
| Period | Direct plan | Regular plan | Benchmark, as published by AMFI NIFTY Healthcare TRI |
|---|---|---|---|
| 1 year | +17.08 % | +15.02 % | +16.99 % |
| 3 years | +19.86 % | +17.66 % | +20.62 % |
| 5 years | +15.60 % | +13.34 % | +15.61 % |
| Since launch | +15.41 % | +13.15 % | +15.60 % |
Past performance may not be sustained in future.
As AMFI's fund performance report prints them for "ITI Pharma & Healthcare Fund"; this site computes no benchmark figure of its own.
How it is computed: NAV to NAV
ITI Pharma and Healthcare Fund - Direct Plan - Growth Option: these run to the newest NAV stored (20 Nov 2026) and are computed here from AMFI's NAV files; AMFI's figures above run to 19 Nov 2026, so the two differ by the days in between.
| Period | Return | From | To |
|---|---|---|---|
| 1 year | +18.01 % in total | 20 Nov 2025 · NAV ₹17.5419 | 20 Nov 2026 · NAV ₹20.7004 |
| 3 years | +19.94 % a year, compounded | 20 Nov 2023 · NAV ₹11.9910 | 20 Nov 2026 · NAV ₹20.7004 |
| 5 years | +15.73 % a year, compounded | 18 Nov 2021 · NAV ₹9.9577 | 20 Nov 2026 · NAV ₹20.7004 |
| Since first NAV | +15.56 % a year, compounded | 11 Nov 2021 · NAV ₹10.0055 | 20 Nov 2026 · NAV ₹20.7004 |
Source: AMFI NAV files (plan code 149268). How to read Report a wrong number
Not enough NAV history stored yet for rolling returns and a monthly SIP.
IDCW (dividend) history
0 declarations · as of 2 Nov 2026 · Source: AMFI
IDCW (formerly "dividend") declared per unit of each IDCW plan, as AMFI lists it.
Calendar-year returns, ITI Pharma and Healthcare Fund - Direct Plan - Growth Option
NAV to NAV · Source: AMFI
| Year | Return | From | To |
|---|---|---|---|
| 2025 | −8.24 % | 31 Dec 2024 · NAV ₹18.5961 | 31 Dec 2025 · NAV ₹17.0636 |
| 2024 | +43.95 % | 29 Dec 2023 · NAV ₹12.9183 | 31 Dec 2024 · NAV ₹18.5961 |
| 2023 | +34.39 % | 30 Dec 2022 · NAV ₹9.6125 | 29 Dec 2023 · NAV ₹12.9183 |
| 2022 | −6.68 % | 31 Dec 2021 · NAV ₹10.3010 | 30 Dec 2022 · NAV ₹9.6125 |
Past performance may not be sustained in future.
Change in the plan's NAV over each calendar year, last NAV to last NAV. Source: AMFI NAV files. How to read
Embed this card
Copy this into any web page. The image carries its source, date and a link back; it is redrawn each night.
- 1 Nov 2026 · TER change: ITI Pharma and Healthcare Fund: AMFI TER file of 1 Nov 2026: direct plan 0.86% (was 0.89%); regular plan 2.57% (was 2.59%); previous file 31 Oct 2026
- 1 Oct 2026 · TER change: ITI Pharma and Healthcare Fund: AMFI TER file of 1 Oct 2026: direct plan 0.89% (was 0.92%); regular plan 2.59% (was 2.62%); previous file 30 Sep 2026
From AMFI's own files (scheme summary documents, NAV history, TER), as they stood on the day shown.
All schemes of ITI Mutual Fund →
Mutual fund investments are subject to market risks; read all scheme related documents carefully.